Press Releases
Jun 11, 2025
COVID-19,Seasonal influenza
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
May 29, 2025
Corporate and finance
Novavax to Participate in Upcoming Investor Conferences
May 8, 2025
Corporate and finance
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights
May 7, 2025
Corporate and finance
Novavax to Participate in BofA Securities 2025 Health Care Conference
May 5, 2025
Corporate and finance
Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
May 1, 2025
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025
Apr 29, 2025
Corporate and finance
Novavax Appoints Charles Newton to Board of Directors
Apr 28, 2025
Statement
COVID-19
Latest update on U.S. FDA BLA for Novavax's COVID-19 Vaccine
Apr 23, 2025
Statement
COVID-19
Latest update on U.S. FDA BLA for Novavax's COVID-19 Vaccine
Showper page